Pfizer (PFE) : Somerset Trust Co reduced its stake in Pfizer by 0.43% during the most recent quarter end. The investment management company now holds a total of 85,089 shares of Pfizer which is valued at $2,765,393 after selling 364 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Apr 13, 2016.Pfizer makes up approximately 1.81% of Somerset Trust Co’s portfolio.
Pfizer opened for trading at $32.3 and hit $32.86 on the upside on Monday, eventually ending the session at $32.61, with a gain of 0.34% or 0.11 points. The heightened volatility saw the trading volume jump to 3,69,99,336 shares. Company has a market cap of $201,665 M.
Other Hedge Funds, Including , Heritage Investors Management Corp boosted its stake in PFE in the latest quarter, The investment management firm added 4,868 additional shares and now holds a total of 430,925 shares of Pfizer which is valued at $14,005,063. Pfizer makes up approx 1.06% of Heritage Investors Management Corp’s portfolio.Stillwater Capital Advisors reduced its stake in PFE by selling 1,859 shares or 0.49% in the most recent quarter. The Hedge Fund company now holds 374,359 shares of PFE which is valued at $12,166,668. Pfizer makes up approx 3.53% of Stillwater Capital Advisors’s portfolio.Greylin Investment Mangement Inc reduced its stake in PFE by selling 950 shares or 2.99% in the most recent quarter. The Hedge Fund company now holds 30,801 shares of PFE which is valued at $982,244. Pfizer makes up approx 0.23% of Greylin Investment Mangement Inc’s portfolio.Foundation Resource Management Inc reduced its stake in PFE by selling 17,425 shares or 1.09% in the most recent quarter. The Hedge Fund company now holds 1,574,276 shares of PFE which is valued at $50,203,662. Pfizer makes up approx 10.12% of Foundation Resource Management Inc’s portfolio.Graybill Bartz Assoc Ltd boosted its stake in PFE in the latest quarter, The investment management firm added 255 additional shares and now holds a total of 89,989 shares of Pfizer which is valued at $2,869,749. Pfizer makes up approx 2.63% of Graybill Bartz Assoc Ltd’s portfolio.
On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.
Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.